Table 3. Summary of results of Ty21a vaccine field trial in Santiago, Chile.

Date of vaccination	Formulation	Doses	Efficacy	Evaluated/effective years	Age range in years	Number	% coverage metropolitan Santiago age group	Reference
May 26-June 2, 1982	Enteric coated capsule	2	59%	2	6–9	8,010	0.022	Black et al 1990 [20]
					10–14	11,048	0.026
					15–17	8,562	0.033
		1	29%	2	6–9	8,009	0.022
					10–14	11,047	0.026
					15–17	8,562	0.033
Mid-July-early September 1983	Enteric coated capsule, short interval	3	62%†	7†	6–17	22,168	0.021	Levine et al 1987 [19]
	Enteric coated capsules, long interval	3	49%	3	6–17	21,598	0.022
	Gelatin capsules, long interval	3	31%	3	6–17	21,541	0.020
	Gelatin capsules, short interval	3	19%	3	6–17	22,379	0.021
October 3–22, 1984	Enteric coated capsule	2	59%*	2*	6–17	66,615	0.074	Ferreccio et al 1989 [21]
		3	62%†	7†	6–17	64,783	0.073
		4	62%†	7†	6–17	58,421	0.065
September-October 1986	Enteric coated capsules	3	62%†	7†	6–9	21,128	0.069	Levine et al 1990 [22]
		3	62%†	7†	10–17	13,568	0.022
	Suspension of reconstituted lyophilate in liquid buffer	3	78%†	5†	6–9	22,586	0.073
		3	78%†	5†	10–17	14,037	0.023

Parameters marked with * are derived from Black et al [20] * and those marked with † from Levine et al 1999 [23] and not from the trial year outcomes. Highlighted trials are categorized as doses equivalent to full efficacy doses or better.